Multiple sclerosis: Comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells
Open Access
- 20 June 2000
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 97 (13) , 7452-7457
- https://doi.org/10.1073/pnas.97.13.7452
Abstract
Copolymer 1 (COP), a standardized mixture of synthetic polypeptides consisting ofl-glutamic acid,l-lysine,l-alanine, andl-tyrosine, has beneficial effects in multiple sclerosis and experimental autoimmune encephalomyelitis. We selected a panel of 721 COP-reactive T cell lines (TCL) from the blood of COP-treated and untreated multiple sclerosis patients and from healthy donors by using the split-well cloning technique. All TCL selected with COP proliferated in response to COP but not to myelin basic protein (MBP). Conversely, 31 control TCL selected with MBP proliferated in response to MBP but not to COP. We used intracellular double-immunofluorescence flow cytometry for quantitative analysis of cytokine production (IL-4, IFN-γ) by the TCL. The majority of the COP-reactive TCL from untreated multiple sclerosis patients and normal donors predominantly produced IFN-γ and, accordingly, were classified as T helper 1 cells (TH1). In contrast, the majority of the COP-reactive TCL from COP-treated patients predominantly (but not exclusively) produced IL-4—i.e., were TH2 (P< 0.05 as assessed by using a suitable preference intensity index). Longitudinal analyses revealed that the cytokine profile of COP-reactive TCL tends to shift from TH1 to TH2 during treatment. Interestingly, although there was no proliferative cross-reaction, about 10% of the COP-reactive TCL responded to MBP by secretion of small amounts of IL-4 or IFN-γ, depending on the cytokine profile of the TCL. These results are consistent with a protective effect of COP-reactive TH2 cells. It is hypothesized that these cells are activated by COP in the periphery, migrate into the central nervous system, and produce immunomodulatory cytokines after local recognition of MBP.Keywords
This publication has 33 references indexed in Scilit:
- The development of Cop 1 (Copaxone®), and innovative drug for the treatment of multiple sclerosis: personal reflectionsImmunology Letters, 1996
- Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responsesJournal of Neuroimmunology, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- T helper cells grown with hapten‐modified cultured Langerhans' cells produce interleukin 4 and stimulate IgE production by B cellsEuropean Journal of Immunology, 1989
- A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple SclerosisNew England Journal of Medicine, 1987
- Cellular immune reactivity within the CNSTrends in Neurosciences, 1986
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymerClinical Immunology and Immunopathology, 1974
- Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogenEuropean Journal of Immunology, 1973
- Suppression of experimental allergic encephalomyelitis by a synthetic polypeptideEuropean Journal of Immunology, 1971